trial

A Study of Brenipatide in Adult Participants With Schizophrenia

NCTId NCT07410507
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 450 (estimated)
Sponsored by Eli Lilly and Company
Primary completion 2027-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
450 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2026-02-10
Primary completion
2027-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Brenipatide

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

103 total
Little Rock, United StatesBellflower, United StatesGarden Grove, United StatesMontclair, United StatesStanford, United StatesTorrance, United StatesWalnut Creek, United StatesHartford, United StatesNew Haven, United StatesCooper City, United StatesLauderhill, United StatesMaitland, United States

Linked catalysts

1
A Study of Brenipatide in Adult Participants With Schizophrenia — primary completion2027-11

Facts & assertions

4 sourced
Enrollment
450
Phase
PHASE2
Primary Completion Date
2027-11
Status
RECRUITING
relationships
The graph out of here
drug
Brenipatide
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person